By Elric Langton | 6th January 2022
Synairgen plc (LSE: SNG), the respiratory company developing SNG001 (inhaled interferon-beta or IFN-beta) for the treatment of COVID-19, has announced another strategic step towards commercialising SNG001. This follows from other strategic appointments; the appointment of Gareth Walters, PhD, to the newly-created role β¦